Ra Pharmaceuticals Inc (RARX) Short Interest Up 41.2% in December

Ra Pharmaceuticals Inc (NASDAQ:RARX) was the recipient of a significant increase in short interest in the month of December. As of December 29th, there was short interest totalling 1,085,182 shares, an increase of 41.2% from the December 15th total of 768,462 shares. Based on an average daily volume of 175,349 shares, the days-to-cover ratio is currently 6.2 days. Approximately 11.7% of the company’s shares are short sold.

Ra Pharmaceuticals (NASDAQ:RARX) opened at $8.49 on Friday. The stock has a market cap of $194.82, a P/E ratio of -3.44 and a beta of 6.29. Ra Pharmaceuticals has a 1-year low of $7.15 and a 1-year high of $27.84.

Ra Pharmaceuticals (NASDAQ:RARX) last issued its quarterly earnings data on Thursday, November 9th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.62) by ($0.06). equities research analysts forecast that Ra Pharmaceuticals will post -2.46 earnings per share for the current fiscal year.

A number of research analysts recently issued reports on the stock. Zacks Investment Research upgraded shares of Ra Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, September 26th. Jefferies Group restated a “buy” rating and set a $25.00 price objective on shares of Ra Pharmaceuticals in a report on Thursday, September 28th. Credit Suisse Group boosted their price objective on shares of Ra Pharmaceuticals from $19.00 to $23.00 and gave the company an “outperform” rating in a report on Friday, November 10th. BMO Capital Markets boosted their price objective on shares of Ra Pharmaceuticals in a report on Tuesday, December 5th. Finally, Royal Bank of Canada restated a “buy” rating and set a $18.00 price objective on shares of Ra Pharmaceuticals in a report on Tuesday, December 5th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $21.90.

Institutional investors and hedge funds have recently made changes to their positions in the business. Schwab Charles Investment Management Inc. lifted its stake in Ra Pharmaceuticals by 70.3% in the second quarter. Schwab Charles Investment Management Inc. now owns 21,800 shares of the company’s stock valued at $409,000 after buying an additional 9,000 shares in the last quarter. Rhumbline Advisers bought a new position in Ra Pharmaceuticals in the second quarter valued at approximately $241,000. Bank of New York Mellon Corp lifted its stake in Ra Pharmaceuticals by 57.7% in the second quarter. Bank of New York Mellon Corp now owns 37,932 shares of the company’s stock valued at $711,000 after buying an additional 13,881 shares in the last quarter. Swiss National Bank bought a new position in Ra Pharmaceuticals in the second quarter valued at approximately $247,000. Finally, JPMorgan Chase & Co. lifted its stake in Ra Pharmaceuticals by 33.7% in the second quarter. JPMorgan Chase & Co. now owns 199,900 shares of the company’s stock valued at $3,746,000 after buying an additional 50,432 shares in the last quarter. 69.64% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Ra Pharmaceuticals Inc (RARX) Short Interest Up 41.2% in December” was published by Stock Observer and is the property of of Stock Observer. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be viewed at https://www.thestockobserver.com/2018/01/14/ra-pharmaceuticals-inc-rarx-short-interest-up-41-2-in-december.html.

About Ra Pharmaceuticals

Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.

Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply